Informed Decision-Making in the Management of Primary Immunodeficiency Diseases (PIDD): Expert Strategies on Immunoglobulin Replacement Therapy

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
CSL Behring

Description:
Primary immunodeficiency diseases (PIDD) are a group of more than 300 rare, chronic disorders in which part of the body’s immune system is missing or functions improperly. While not contagious, these diseases are caused by hereditary or genetic defects, and, although some disorders present at birth or in early childhood, the disorders can affect anyone, regardless of age or gender. Some affect a single part of the immune system; others may affect one or more components of the system. And while the diseases may differ, they all share one common feature: each result from a defect in one of the functions of the body's normal immune system. Fortunately for patients with primary immunodeficiency disorders, the treatment paradigm has exploded in the past 10 years, giving medical directors and clinicians many more options in managing the PIDD patient population. Leading the way in this quickly growing arena are immunoglobulin therapies, which have shown improved efficacy and safety for patients with PIDDs. While these types of therapies have been available for many years, it is only recently that so many additional options have become available for the PIDD patient population. It is imperative that medical directors, practicing physicians, nurses and other healthcare professionals who manage PIDD patient populations have a solid understanding of differing options to optimize both costs and patient outcomes in their therapeutic application.

Upon completion of this activity, participants will be able to:

  • Examine early signs and symptoms of primary immunodeficiency (PIDD), and employ appropriate techniques to identify patients with PIDD

  • Analyze the mechanisms of action, efficacy, and safety profiles of current and emerging immunoglobulin (Ig) replacement therapies and strategies for their use in PIDD

  • Compare and contrast the key differences between subcutaneous and intravenous therapy, including the advantages and disadvantages of both options in various patient populations

  • Explore the total cost of care for PIDD, including direct costs associated with drug therapy and associated infections from non-treatment, as well as indirect costs

  • Assess recent pharmacoeconomic studies pertaining to Ig replacement therapy and the budgetary implications of these data in a managed care framework

  • Review the managed care considerations on Ig replacement therapies and explore where these agents fit in the PIDD management paradigm
     

Faculty: Richard Wasserman, MD, PhD
Medical Director, Pediatric Allergy and Immunology
Medical City Children’s Hospital

Disclosure:

Dr. Wasserman serves as a consultant for Korean Green Cross, Takeda, and Therapure. He has received grant/research support from CSL Behring, Kedrion, Korean Green Cross, Octapharma, and Takeda. He serves on the speaker's bureau for CSL Behring and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
CSL Behring

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue